The FDA Oncology Center of Excellence has launched Project Optimus, whose goal is to reform the dose optimization and dose selection paradigm in oncology drug development. The project’s overall aim is to reduce toxicity without impact on efficacy. Existing platforms have been considered by many to be the “go-to” antibody-based technologies for multiplexed immune response monitoring. Download this white paper to compare and learn about the performance of assays usable for FDA Project Optimus.
Please check the highlighted fields and try again.
Please enter your first and last name.
Please enter the name of the company or institution you work at.
Please enter your mailing address.
Please enter the e-mail address you would like to be contacted at.